1. FOXO1 regulates oncogenic PKC-ι expression in melanoma inversely to c-Jun in an autocrine manner via IL-17E and ICAM-1 activation
   WISHRAWANA RATNAYAKE et al, 2018, wasj CrossRef
2. null
   Wishrawana S. Ratnayake et al, 2019 CrossRef
3. Targeting Rho GTPase Signaling Networks in Cancer
   Natasha S. Clayton et al, 2020, Front. Cell Dev. Biol. CrossRef
4. Evaluating the current status of protein kinase C (PKC)-protein kinase D (PKD) Signalling Axis as a novel therapeutic target in ovarian Cancer
   Komal Tyagi et al, 2020, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
5. Atypical PKCs activate Vimentin to facilitate prostate cancer cell motility and invasion
   Wishrawana S. Ratnayake et al, 2021, Cell Adhesion & Migration CrossRef
6. Targeting the Hippo Pathway in Prostate Cancer: What’s New?
   Kelly Coffey, 2021, Cancers CrossRef
7. Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
   Takahito Kawano et al, 2021, Pharmaceutics CrossRef
8. Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment
   Soghra Bagheri et al, 2022, Pharmaceutics CrossRef
9. Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer
   Takahito Kawano et al, 2022, Cancers CrossRef
10. 14-3-3 and Smad2/3 are crucial mediators of atypical-PKCs: Implications for neuroblastoma progression
    S. Breedy et al, 2023, Front. Oncol. CrossRef